本文言語 | English |
---|---|
ページ(範囲) | 491-493 |
ページ数 | 3 |
ジャーナル | Japanese journal of infectious diseases |
巻 | 73 |
号 | 6 |
DOI | |
出版ステータス | Published - 2020 |
ASJC Scopus subject areas
- 微生物学(医療)
- 感染症
UN SDG
この成果は、次の持続可能な開発目標に貢献しています
文献へのアクセス
他のファイルとリンク
引用スタイル
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Japanese journal of infectious diseases, Vol. 73, No. 6, 2020, p. 491-493.
研究成果: Article › 査読
}
TY - JOUR
T1 - Cluster-based approach to coronavirus disease 2019 (COVID-19) response in Japan, from February to April 2020
AU - The Expert Members of The National COVID-19 Cluster Taskforce at The Ministry of Health, Labour, Welfare, Japan
AU - Oshitani, Hitoshi
N1 - Funding Information: All experts listed in the appendix developed the concept of the report. Kazuaki Jindai and Natalie Linton wrote the first draft, with equal contributions. Tomoya Saito, Yuki Furuse, and Hitoshi Oshitani provided additional feedback on the first draft. All authors edited and finalized the manuscript. Secretariat members of the taskforce also contributed to this manuscript. The authors would like to acknowledge the following institutions for their contribution to support the cluster-based approach: public health centers, prefectural governments, public health institutes, and medical facilities. The authors would also like to thank volunteer members (Kozue Amemiya, Kayako Chishima, Aya Fujiwara, Yoko Hamasaki, Naomi Ikeda, Keiya Inoue, Sachi Ishida, Tomoe Mashiko, Kota Ninomiya, Akiko Sayama, Ayaka Takeuchi, Hiroto Tanaka, Fumie Tokuda, Shogo Yaegashi, Lisa Yamasaki, Fumi Yoshimatsu, and Mariko Kanamori), external experts (Kyoko Fujisawa and Megumi Kawashima), and the Bureau of International Health Cooperation at National Center for Global Health and Medicine for information gatherings and data cleaning. Natalie Linton and Sung-mok Jung received a graduate study scholarship from the Ministry of Education, Culture, Sports, Science and Technology, Japan. Akira Endo is financially supported by The Nakajima Foundation and the Alan Turing Institute and received a research grant from Taisho Pharmaceutical Co., Ltd. The opinions expressed here are that of the authors and do not reflect the official policy of the MHLW.
PY - 2020
Y1 - 2020
UR - http://www.scopus.com/inward/record.url?scp=85094825221&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094825221&partnerID=8YFLogxK
U2 - 10.7883/yoken.JJID.2020.363
DO - 10.7883/yoken.JJID.2020.363
M3 - Article
C2 - 32611985
AN - SCOPUS:85094825221
SN - 1344-6304
VL - 73
SP - 491
EP - 493
JO - Japanese medical journal
JF - Japanese medical journal
IS - 6
ER -